Published in AIDS Res Ther on May 04, 2017
Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One (2009) 8.37
Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. Lancet (2009) 7.96
23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial. Lancet (2000) 4.23
Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions. Clin Infect Dis (2005) 3.76
The 3-year renal safety of a tenofovir disoproxil fumarate vs. a thymidine analogue-containing regimen in antiretroviral-naive patients. AIDS (2008) 3.17
Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study. J Infect Dis (2013) 3.04
The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS (2007) 2.58
Adverse effects of antiretroviral therapy for HIV infection. CMAJ (2004) 2.04
Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. AIDS (2009) 1.81
The calibrated population resistance tool: standardized genotypic estimation of transmitted HIV-1 drug resistance. Bioinformatics (2009) 1.80
HIV-associated renal diseases and highly active antiretroviral therapy-induced nephropathy. Clin Infect Dis (2006) 1.64
Epidemiology of hypertension in low-income countries: a cross-sectional population-based survey in rural Uganda. J Hypertens (2011) 1.61
Tenofovir-associated Fanconi syndrome: review of the FDA adverse event reporting system. AIDS Patient Care STDS (2008) 1.57
An HIV-1 natural history cohort and survival times in rural Uganda. AIDS (1997) 1.56
Prevalence of dyslipidaemia and associated risk factors in a rural population in South-Western Uganda: a community based survey. PLoS One (2015) 1.50
Renal safety of tenofovir in HIV treatment-experienced patients. AIDS (2004) 1.50
The general population cohort in rural south-western Uganda: a platform for communicable and non-communicable disease studies. Int J Epidemiol (2013) 1.48
Association between tenofovir exposure and reduced kidney function in a cohort of HIV-positive patients: results from 10 years of follow-up. Clin Infect Dis (2012) 1.40
Plasma cholesterol and related lipid levels of seemingly healthy public service employees in Kampala, Uganda. Afr Health Sci (2006) 1.08
Antiretroviral therapy and sexual behavior in Uganda: a cohort study. AIDS (2011) 1.06
Recent developments in HIV and the kidney. Curr Opin Infect Dis (2009) 1.06
Screening for hepatitis C among HIV positive patients at Mulago hospital in Uganda. Afr Health Sci (2009) 1.04
Tenofovir renal safety in HIV-infected patients: results from the SCOLTA Project. Biomed Pharmacother (2007) 1.03
Antiretroviral therapy and the human immunodeficiency virus--improved survival but at what cost? Diabetes Obes Metab (2007) 1.01
Morbidity in HIV-1-infected individuals before and after the introduction of antiretroviral therapy: a longitudinal study of a population-based cohort in Uganda. HIV Med (2011) 1.00
Using verbal autopsy to assess the prevalence of HIV infection among deaths in the ART period in rural Uganda: a prospective cohort study, 2006-2008. Popul Health Metr (2011) 1.00
Septicaemia in a population-based HIV clinical cohort in rural Uganda, 1996-2007: incidence, aetiology, antimicrobial drug resistance and impact of antiretroviral therapy. Trop Med Int Health (2010) 0.99
Tenofovir use and urinary biomarkers among HIV-infected women in the Women's Interagency HIV Study (WIHS). J Acquir Immune Defic Syndr (2013) 0.97
The pathology induced by highly active antiretroviral therapy against human immunodeficiency virus: an update. Curr Med Chem (2006) 0.92
Progression of renal impairment under therapy with tenofovir. AIDS (2005) 0.91
Toxic metabolic syndrome associated with HAART. Expert Opin Drug Metab Toxicol (2006) 0.89
The metabolic toxicities of antiretroviral therapy. Int J STD AIDS (2001) 0.88
HIV and the kidney: a spotlight on racial disparities. J Infect Dis (2008) 0.85
Low Incidence of Renal Dysfunction among HIV-Infected Patients on a Tenofovir-Based First Line Antiretroviral Treatment Regimen in Myanmar. PLoS One (2015) 0.85
Risk Factors and Seroprevalence of Hepatitis C among Patients Hospitalized at Mulago Hospital, Uganda. J Trop Med (2011) 0.83
From antiretroviral therapy access to provision of third line regimens: evidence of HIV Drug resistance mutations to first and second line regimens among Ugandan adults. BMC Res Notes (2016) 0.75
The effect of Tenofovir on renal function among Ugandan adults on long-term antiretroviral therapy: a cross-sectional enrolment analysis. AIDS Res Ther (2016) 0.75
COHORT PROFILE: The Complications of Long-Term Antiretroviral Therapy study in Uganda (CoLTART), a prospective clinical cohort. AIDS Res Ther (2017) 0.75
Cardiometabolic risk among HIV-POSITIVE Ugandan adults: prevalence, predictors and effect of long-term antiretroviral therapy. Pan Afr Med J (2017) 0.75